Emtora Biosciences
1 known investors
Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).
BiotechLongevityMedical Devices